Experimental Treatments for Myasthenia Gravis

Batoclimab is an experimental antibody therapy being developed for the treatment of a number of autoimmune diseases, including generalized MG. The therapy, administered in the form of under-the-skin (subcutaneous) injections, is designed to lower the levels of MG-causing antibodies in order to ease disease severity.

CABA-201 is an investigational CAR T-cell therapy that’s being developed for the treatment of MG. Administered via a one-time intravenous, or into-the-bloodstream, infusion after a course of chemotherapy, the therapy is designed to target disease-driving immune B-cells to potentially reduce MG severity.

Cladribine is a short-course oral therapy being developed for generalized MG. Administered as oral capsules, it’s designed to lower the levels of the immune cells that drive inflammatory attacks in MG.

Descartes-08 is an investigational CAR T-cell therapy that’s being developed for the treatment of MG. Administered via intravenous, or into-the-vein, infusions, it is designed to lower the levels of immune B-cells and potentially reduce disease severity.

DNTH103 is an investigational antibody-based therapy being developed for the treatment of generalized MG. Administered in the form of subcutaneous, or under-the-skin, injections that can be self-administered, it is designed to block the activation of the complement system, a part of the immune system thought to contribute to disease’s autoimmune attacks.

Firdapse (amifampridine) is being developed to treat muscle weakness in a rare type of MG called MuSK-MG. It is currently in Phase 3 trials in these patients.

Gefurulimab is an experimental therapy being developed for the treatment of generalized MG. Administered in the form of subcutaneous, or under-the-skin, injections that can be self-administered, it is designed to block the activation of the complement system, a part of the immune system that’s thought to be involved in the disease’s autoimmune attacks.

Inebilizumab is an antibody-based therapy being developed for the treatment of MG. Administered via intravenous, or into-the-vein, infusions every six months, the therapy is expected to reduce the levels of certain immune cells that drive MG and ease disease symptoms.

KYV-101 is an investigational CAR T-cell therapy that’s being developed for the treatment of MG. Administered via a single infusion into the bloodstream, or intravenously, after a short course of chemotherapy, it is designed to lower the levels of immune B-cells and potentially ease disease severity.

Nipocalimab is an experimental antibody therapy being developed for the treatment of a number of autoimmune diseases, including generalized MG. The therapy, administered via into-the-vein (intravenous) infusions, is designed to lower the levels of MG-causing antibodies in order to ease disease severity.

NMD670 is an investigational oral therapy being developed for MG and a number of rare diseases. The therapy, administered twice daily in the form of oral tablets, is designed to improve nerve-muscle communication and restore muscle function.

A combination of the antibody therapy pozelimab and an RNA-based therapy called cemdisiran is being developed for the treatment of MG. Administered in the form of monthly subcutaneous, or under-the-skin, injections, the combination is designed to block the activation of the complement system, a part of the immune system thought to be involved in the disease’s autoimmune attacks.

Rituximab is an antibody-based therapy that’s approved for some blood cancers and autoimmune conditions. It is not formally approved for the treatment of MG, but it may be used off-label in some patients with treatment-resistant disease. The therapy is administered via intravenous, or into-the-vein, infusions.

Telitacicept is an investigational B-cell targeting therapy being developed as a potential treatment for MG. The therapy, administered in the form of under-the-skin (subcutaneous) injections, is designed to reduce the activity of immune B-cells that drive MG.